Teacher Retirement System of Texas Purchases 16,891 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Teacher Retirement System of Texas lifted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 18.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 109,531 shares of the company’s stock after acquiring an additional 16,891 shares during the quarter. Teacher Retirement System of Texas’ holdings in Roivant Sciences were worth $1,296,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after acquiring an additional 1,507 shares during the last quarter. Quarry LP lifted its stake in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares during the last quarter. Blue Trust Inc. boosted its holdings in Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after acquiring an additional 6,667 shares during the period. Finally, HighTower Advisors LLC purchased a new stake in Roivant Sciences in the fourth quarter worth $121,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of Roivant Sciences stock in a transaction on Monday, January 13th. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the acquisition, the director now owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Eric Venker sold 434,478 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the sale, the chief operating officer now directly owns 1,127,290 shares of the company’s stock, valued at approximately $12,197,277.80. The trade was a 27.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,573,245 shares of company stock worth $17,079,242 over the last 90 days. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Price Performance

ROIV stock opened at $10.38 on Friday. Roivant Sciences Ltd. has a 1-year low of $9.96 and a 1-year high of $13.06. The business has a 50-day moving average price of $10.74 and a 200 day moving average price of $11.41. The company has a market capitalization of $7.41 billion, a P/E ratio of -69.20 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $17.10.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.